

AMICASIL

Antibiotics

Recommended treatment of:

Short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including *Pseudomonas aeruginosa*, *E.Coli*, *Proteus indolo+* and *indolo-*, *Providencia*, *Klebsiella enterobacter* strains, *Serratia*, and *Acinetobacter*.

For further detailed description, see back side.

Route of administration:

i.m; i.v.

Active principle:

Amikacin Sulphate

Dosage & pack size:

500 mg/2 ml – box of 10 ampoules

Registered for use in:

Italy, Azerbaijan, Georgia



Recommended treatment of:

- bacteremia, septicemia and neonatal sepsis;
- serious infections of respiratory tract, infections of bones and articulations, SNC infections (including meningitis), intra-abdominal infections including peritonitis, burns and post-surgery infections including vascular surgery infections;
- serious urinary tract recurring infections due to Gram-negative organisms;
- infections caused by staphylococcus: Amikacin may be adopted as attack therapy in ascertained or presumed staphylococcal infections, when the subject is allergic to other antibiotics or in infections caused by staphylococcus and Gram-negative organisms;
- neonatal sepsis when the antibiotic sensitivity test excludes the introduction of any other aminoglycosides;

Amikacin is active against some strains of Gram-negative bacteria resistant to gentamicin, tobramycin, and kanamycin, including *Pseudomonas aeruginosa*, *Proteus rettgeri*, *Providencia stuartii*, and *Serratia marcescens*.

